Last reviewed · How we verify

Sotyktu — Competitive Intelligence Brief

Sotyktu (DEUCRAVACITINIB) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine Kinase 2 Inhibitor [EPC]. Area: Immunology.

marketed Tyrosine Kinase 2 Inhibitor [EPC] Non-receptor tyrosine-protein kinase TYK2 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Sotyktu (DEUCRAVACITINIB) — Bristol-Myers Squibb. Sotyktu works by blocking the TYK2 enzyme, which is involved in the inflammatory response and contributes to the development of psoriasis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sotyktu TARGET DEUCRAVACITINIB Bristol-Myers Squibb marketed Tyrosine Kinase 2 Inhibitor [EPC] Non-receptor tyrosine-protein kinase TYK2 2022-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine Kinase 2 Inhibitor [EPC] class)

  1. Bristol-Myers Squibb · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sotyktu — Competitive Intelligence Brief. https://druglandscape.com/ci/deucravacitinib. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: